Medtronic’s most recent trend suggests a bearish bias. One trading opportunity on Medtronic is a Bear Call Spread using a strike $121.00 short call and a strike $126.00 long call offers a potential 33.69% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $121.00 by expiration. The full premium credit of $1.26 would be kept by the premium seller. The risk of $3.74 would be incurred if the stock rose above the $126.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Medtronic is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Medtronic is bearish.
The RSI indicator is at 30.06 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Medtronic
Medtronic study shows patients with high blood pressure are interested in an interventional procedure treatment option
Thu, 04 Nov 2021 13:38:00 +0000
Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced findings from a new study of the Patient Preferences for the Treatment of Hypertension. The findings will be presented later today during the “What’s Novel in Interventional Hypertension session” at the 33rd Transcatheter Cardiovascular Therapeutics (TCT 2021) conference, the annual scientific symposium of the Cardiovascular Research Foundation.
Medtronic (MDT) Stock Sinks As Market Gains: What You Should Know
Wed, 03 Nov 2021 21:50:09 +0000
Medtronic (MDT) closed at $121.18 in the latest trading session, marking a -0.1% move from the prior day.
Intersect ENT (XENT) Q3 Loss Widens, Sell-Off Process On Track
Wed, 03 Nov 2021 15:07:03 +0000
An increase in Intersect ENT’s (XENT) operating costs puts pressure on its Q3 bottom line.
Engineering Impact: Employee Stories
Tue, 02 Nov 2021 18:16:07 +0000
Excerpts from the 2021 Medtronic Integrated Performance Report
Rune Labs and Medtronic Partner to Evaluate Use of Medtronic BrainSense™ Data in Rune’s Software for Precision Neurology
Tue, 02 Nov 2021 10:00:00 +0000
Rune Labs, a company using aggregated brain data to empower the development and delivery of precision medicines for neurological and psychiatric diseases, and Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced a new project designed to better understand the effects of neurostimulation in order to improve patient care. This collaboration will use Rune’s proprietary software platform to integrate, analyze, and display data captured from Medtronic’s Percept™ PC Neur
Follow Us on Facebook